Amgen to buy KAI Pharma for $315M cash Bizjournals.com (blog) KAI's lead drug is in Phase II trials for hyperparathyroidism in patients with chronic kidney disease, but Amgen said it would provide a loan for planning of a Phase III trial prior to the deal closing. The drug, called KAI-4169, is an intravenous ... Amgen buys South City pharmaceutical company for $315 million Amgen to Buy KAI Pharma for $315 Million Amgen Boosts Pipeline, Adds SHPT Drug, KAI-4169, in $315M KAI Buy |
